secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001493152-23-028684
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharma Q1 revenue up 17% to $9.0M; net income up 267% to $1.1M
--------------------------------------------------------------------

- Revenue $9.0M (+16.9% YoY); operating profit $1.6M (+60% YoY).
- Net income attributable to common shareholders $1.1M (+267% YoY).
- Growth driven by launch of Elite Laboratories label product line.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315223028684/0001493152-23-028684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315223028684/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-028684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer